VISTA has been traditionally recognized for its role in suppressing T cell-associated responses, contributing to immune escape and survival in several human cancers, including prostate cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), acute myeloid leukemia (AML), pancreatic cancer, cutaneous melanoma, metastatic melanoma, hepatocellular carcinoma, ovarian cancer, oral squamous cell carcinoma, and gastric cancer. This evidence concerns the gene VSIR and acute myeloid leukemia.